Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PeptiStrong is a patented, plant-based peptide ingredient derived from the enzymatic hydrolysis of fava bean proteins, developed using artificial intelligence by Nuritas to support muscle health, strength, recovery, and endurance. Clinically studied, it consists of a network of bioactive cell-signaling peptides that stimulate muscle protein synthesis, suppress muscle breakdown, and modulate biomarkers related to blood sugar, bone health, and metabolism[1][4][6][7][8]. PeptiStrong is as effective as leucine at a fraction of the dose, outperforms HMB and creatine in several biomarker endpoints, and can quadruple the muscle protein synthesis effect compared to whey or milk proteins[1][2][3][8][9]. Its mechanisms include mTOR pathway upregulation and myostatin reduction, contributing to muscle anabolism and reduced loss during catabolic states, such as immobilization or rapid weight loss. It holds self-affirmed GRAS and Health Canada approvals[2][4][7]. PeptiStrong can be used as a dietary supplement or food ingredient and is optimized for bioavailability with demonstrated benefit for populations ranging from active adults to the elderly and those on weight-loss medications[3][4][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PeptiStrong.